[Kinematic movement analyses and their application in psychiatry].
There is a long tradition to develop valid instruments for the exact assessment of psycho-motor dysfunctions in psychiatry. However, progress is hampered by the complexity of emotionally driven movements in psychiatric patients. Methods used up to now either remains unspecific due to only qualitative measurements or focus on the neurophysiological aspects too much. Thus, the results accomplished so far are only very general unspecific concerning different groups of psychiatric patients. In this paper, two own methods are presented which are aimed to avoid the two poles above mentioned. Kinematic analyses of facial expressions as well as handwriting movements provide quantitative and quite specific informations about psycho-motor dysfunctions of psychiatric patients and the effects of psychotropic substances. Thus, these methods are well suitable for relating them to other neurobiological parameters in order to contribute to the pathophysiological understanding of psycho-motor symptoms in psychiatric patients.
Juckel
Georg
G
Klinik für Psychiatrie und Psychotherapie, Charité, Campus Mitte Berlin. georg.juckel@charite.de
Mergl
Roland
R
Hegerl
Ulrich
U
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001696:Biomechanical Phenomena / Q000295:instrumentation*; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D004644:Emotions / Q000502:physiology; D005149:Facial Expression; D007839:Functional Laterality; D006236:Handwriting; D006801:Humans; D001523:Mental Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D019964:Mood Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D009460:Neurologic Examination / Q000187:drug effects; D009483:Neuropsychological Tests; D011237:Predictive Value of Tests; D011596:Psychomotor Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D011619:Psychotropic Drugs / Q000009:adverse effects* / Q000627:therapeutic use; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D055502:Secondary Prevention; D012815:Signal Processing, Computer-Assisted / Q000295:instrumentation*; D014463:Ultrasonography / Q000295:instrumentation*
D014150:Antipsychotic Agents; D011619:Psychotropic Drugs